281 related articles for article (PubMed ID: 28110235)
1. Relationship between expression of vascular endothelial growth factor and the proliferation of prolactinomas.
Li N; Jiang Z
Clin Neurol Neurosurg; 2017 Feb; 153():102-106. PubMed ID: 28110235
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
Luque GM; Perez-Millán MI; Ornstein AM; Cristina C; Becu-Villalobos D
J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
[TBL] [Abstract][Full Text] [Related]
3. Ghrelin and growth hormone (GH) secretagogue receptor (GHSR) mRNA expression in human pituitary adenomas.
Kim K; Arai K; Sanno N; Osamura RY; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2001 Jun; 54(6):759-68. PubMed ID: 11422110
[TBL] [Abstract][Full Text] [Related]
4. Relationship between expression of vascular endothelial growth factor and intratumoral hemorrhage in human pituitary adenomas.
Jin Kim Y; Hyun Kim C; Hwan Cheong J; Min Kim J
Tumori; 2011; 97(5):639-46. PubMed ID: 22158497
[TBL] [Abstract][Full Text] [Related]
5. The expression of thyrotrophin-releasing hormone receptor 1 messenger ribonucleic acid in human pituitary adenomas.
Kim K; Arai K; Sanno N; Teramoto A; Shibasaki T
Clin Endocrinol (Oxf); 2001 Mar; 54(3):309-16. PubMed ID: 11298082
[TBL] [Abstract][Full Text] [Related]
6. Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-endothelial function of VEGF in pituitary tumours.
Onofri C; Theodoropoulou M; Losa M; Uhl E; Lange M; Arzt E; Stalla GK; Renner U
J Endocrinol; 2006 Oct; 191(1):249-61. PubMed ID: 17065408
[TBL] [Abstract][Full Text] [Related]
7. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas.
Kim K; Yoshida D; Teramoto A
Endocr Pathol; 2005; 16(2):115-21. PubMed ID: 16199896
[TBL] [Abstract][Full Text] [Related]
8. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D
Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350
[TBL] [Abstract][Full Text] [Related]
9. Microvascular density and vascular endothelial growth factor expression in normal pituitary tissue and pituitary adenomas.
Viacava P; Gasperi M; Acerbi G; Manetti L; Cecconi E; Bonadio AG; Naccarato AG; Acerbi F; Parenti G; Lupi I; Genovesi M; Martino E
J Endocrinol Invest; 2003 Jan; 26(1):23-8. PubMed ID: 12602530
[TBL] [Abstract][Full Text] [Related]
10. What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics.
Gürlek A; Karavitaki N; Ansorge O; Wass JA
Eur J Endocrinol; 2007 Feb; 156(2):143-53. PubMed ID: 17287403
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein hormone alpha-subunit secretion in prolactinomas and in non-functioning adenomas: relation with the tumour size.
Warnet A; Porsova-Dutoit I; Lahlou N; Seret-Begue D; Lajeunie E; Chanson P; Woimant F; Lot G; Guillausseau PJ; Roger M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):177-84. PubMed ID: 7523001
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor production and regulation in rodent and human pituitary tumor cells in vitro.
Lohrer P; Gloddek J; Hopfner U; Losa M; Uhl E; Pagotto U; Stalla GK; Renner U
Neuroendocrinology; 2001 Aug; 74(2):95-105. PubMed ID: 11474217
[TBL] [Abstract][Full Text] [Related]
13. Cytokine expression in human anterior pituitary adenomas.
Green VL; Atkin SL; Speirs V; Jeffreys RV; Landolt AM; Mathew B; Hipkin L; White MC
Clin Endocrinol (Oxf); 1996 Aug; 45(2):179-85. PubMed ID: 8881450
[TBL] [Abstract][Full Text] [Related]
14. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas.
Dogansen SC; Yalin GY; Tanrikulu S; Tekin S; Nizam N; Bilgic B; Sencer S; Yarman S
Pituitary; 2018 Aug; 21(4):347-354. PubMed ID: 29460202
[TBL] [Abstract][Full Text] [Related]
16. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
17. Thrombospondin-1 and transforming growth factor-β1 levels in prolactinoma and their clinical significance.
Jiang M; Mou CZ; Han T; Wang M; Yang W
J Int Med Res; 2012; 40(4):1284-94. PubMed ID: 22971480
[TBL] [Abstract][Full Text] [Related]
18. Prop-1 gene expression in human pituitary tumors.
Nakamura S; Ohtsuru A; Takamura N; Kitange G; Tokunaga Y; Yasunaga A; Shibata S; Yamashita S
J Clin Endocrinol Metab; 1999 Jul; 84(7):2581-4. PubMed ID: 10404841
[TBL] [Abstract][Full Text] [Related]
19. VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas.
Corlan AS; Cîmpean AM; Melnic E; Raica M; Sarb S
Eur J Histochem; 2019 Mar; 63(1):. PubMed ID: 30838843
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effect of thalidomide on the growth, secretory function and angiogenesis of estrogen-induced prolactinoma in Fischer 344 rats.
Stepień H; Lawnicka H; Mucha S; Wagrowska-Danilewicz M; Stepień B; Siejka A; Komorowski J
Life Sci; 2006 Sep; 79(18):1741-8. PubMed ID: 16846617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
